A trial of amivantamab, lazertinib and osimertinib for non small cell lung cancer (MARIPOSA)

Please note

This trial is no longer recruiting patients. We hope to add results when they are available.

Overview

Cancer types:

Lung cancer, Non small cell lung cancer (NSCLC), Secondary cancers

Status:

Closed

Phase:

Phase 3

Details

This trial is looking at whether amivantamab with lazertinib is better than osimertinib by itself or lazertinib by itself for non small cell lung cancer.

It is open to people with non small lung cancer (NSCLC) that has spread into the nearby tissue () or to another part of the body (advanced). It is only for people whose cancer has a change () in the epidermal growth factor receptor (EGFR).